Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication.
Ing S Tiong, Sun Loo
https://pubmed.ncbi.nlm.nih.gov/36902217/Actively Recruiting
Led by National Cancer Institute (NCI) · Updated on 2026-11-02
2000
Participants Needed
360
Research Sites
N/A
Total Duration
Researchers are evaluating a Master Screening and Reassessment Protocol MSRP to improve the matching of patients with myeloid cancers, such as acute myeloid leukemia AML or myelodysplastic syndrome MDS, to appropriate clinical trials or standard treatments. This study focuses on using bone marrow and blood tests to detect biomarkers that guide treatment decisions, aiming to assign participants quickly to targeted treatment studies or standard care pathways. The study also assesses the ability to organize and process data rapidly to support treatment assignments. Participants undergo bone marrow aspiration and blood collection for rapid genetic testing to identify mutations that may be targeted by specific therapies within various substudies. If no targetable mutation is found, participants may be assigned to novel combination drug studies or continue standard of care through the Tier Advancement Pathway TAP. Treatments studied include various drug regimens involving agents such as azacitidine, venetoclax, cytarabine, daunorubicin, and others, administered intravenously, subcutaneously, or orally according to specific schedules. Some participants may also receive hematopoietic stem cell transplantation with conditioning regimens. Treatment cycles vary in length and number depending on the assigned substudy. Throughout the study, participants have multiple bone marrow aspirations, biopsies, blood sample collections, and imaging tests such as echocardiography or MUGA scans for monitoring. Researchers assess timing for treatment assignment, response rates, adverse events, and overall survival among other outcomes. The study includes ongoing reassessment to allow movement to higher tier treatment options when appropriate. Participation may last for extended periods, with some regimens continuing up to two years or more, depending on response and disease progression.
CONDITIONS
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cancer Institute (NCI)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | myeloMATCH screening protocol | Current standard‑of‑care pathway |
|---|---|---|
| What it is | A screening step where blood and bone marrow are tested for biomarkers to guide assignment into targeted treatment trials or to standard‑of‑care via Tier Advancement Pathway | Usual clinical practice involves standard treatment assignment (for newly diagnosed AML/MDS) based on established guidelines without molecular stratification |
| Role in trial | Primary screening mechanism used to route participants into precision‑medicine treatment substudies or SOC | Not part of the trial; represents usual care outside the investigational protocol |
| Primary use | Matching participants to appropriate myeloMATCH treatment substudy or SOC via Tier Advancement Pathway | Deliver disease‑directed therapy (induction/consolidation) guided by clinical and molecular risk per guidelines |
| How it is done | Rapid biomarker testing using blood and bone marrow specimens to guide trial or SOC assignment | Assignment based on clinical evaluation, genetic testing as per routine workflow without centralized rapid screening |
| Evidence status | Feasibility being evaluated; evidence on speed of trial matching and assignment is pending | Supported by clinical guidelines and widespread clinical use, with proven outcomes in remission and survival |
| Important risks | Risks are related to bone marrow sampling; no treatment risks assessed at screening stage | Risks vary based on therapy chosen (e.g. chemotherapy toxicities) |
| Important limitations | Does not itself treat disease; effectiveness depends on availability of matched substudies | May lack personalization based on molecular subtype; outcomes vary by fitness and disease biology |
| Patient impact | Participating may enable quicker assignment to targeted treatment substudy when available | Patients receive established therapies with known benefit but possibly slower matching to targeted options |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are evaluated for eligibility through bone marrow aspiration and blood sample collection for rapid genetic testing to detect biomarkers related to their myeloid cancer.
1 to 2 visits
Duration - Within 10 days of specimen receipt for subsequent therapy
Based on test results, participants are assigned to a specific treatment substudy targeting their cancer's mutations or to the Tier Advancement Pathway (TAP) for standard care if no suitable substudy exists.
1 visit
Duration - Varies by regimen; treatment cycles repeat every 21 or 28 days and can continue for up to 2 years in some cases
Participants receive study treatments according to the assigned substudy, which may include various drug regimens administered intravenously, orally, or subcutaneously, or may undergo hematopoietic stem cell transplantation with conditioning.
Multiple visits throughout treatment cycles
Duration - Ongoing throughout study participation
Participants undergo regular bone marrow aspirations, biopsies, blood collections, and imaging tests such as echocardiography or MUGA to monitor disease status, treatment response, and safety. Reassessment may allow moving to higher tier treatments or continued standard care.
Regular visits as determined by treatment protocol
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
41
Have more questions? Get in touch with our team for quick support
Ing S Tiong, Sun Loo
https://pubmed.ncbi.nlm.nih.gov/36902217/National Cancer Institute (NCI)
Lead Sponsor